SPC473
“atezolizumab”
Status:
UmsóknApplication date:
16.6.2024Application published:
15.7.2024
Max expiry date:
20.9.2032Medicine name:
TecentriqMedicine for children:
Yes
Timeline
Today
16.6.2024Application
15.7.2024Publication
20.9.2032Expires
Marketing license
IS authorization number:
EU/1/17/1220Date:
5.10.2017
Foreign authorization number:
EU/1/17/1220Date:
21.9.2017
Owner
Name:
F. Hoffmann-La Roche AGAddress:
Grenzacherstrasse 124, 4070 Basel CH
Agent
Name:
Örn Þór slf.Address:
Klukkuvöllum 17, 221 Hafnarfirði
Patent
Number:
EP4209510